Drug – bio-affecting and body treating compositions – Plant material or plant extract of undetermined constitution...
Reexamination Certificate
2011-04-12
2011-04-12
Leith, Patricia (Department: 1655)
Drug, bio-affecting and body treating compositions
Plant material or plant extract of undetermined constitution...
C514S008100
Reexamination Certificate
active
07923043
ABSTRACT:
Methods for protection of a human from SVFS comprise the administration of a flavonoid compound of the basic structures 2-phenyl-4H-1-benzopyran or 2-phenyl-4-keto-1-benzopyran or glycosides thereof, alone or, optionally, together with one or more of an olive kernel extract, a non-bovine sulfated proteoglycan, bitter willow extract, a D-hexosamine sulfate, S-adenosylmethionine, folic acid, vitamin B12 and a serotonin inhibitor. Such treatment prevents, reduces or eliminates SVFS in patients receiving as much as 300-3000 mg/day of niacin therapeutically, whether administered prior to, or along with, an anti-SVFS composition.
REFERENCES:
patent: 5223257 (1993-06-01), Arora
patent: 5250529 (1993-10-01), Theoharides
patent: 5260335 (1993-11-01), Wagner et al.
patent: 5648355 (1997-07-01), Theoharides
patent: 5795905 (1998-08-01), McCarthy et al.
patent: 5804594 (1998-09-01), Murad
patent: 5855884 (1999-01-01), Theoharides
patent: 5876744 (1999-03-01), Della Valle et al.
patent: 5972999 (1999-10-01), Murad
patent: 5980865 (1999-11-01), Ahmed
patent: 5994357 (1999-11-01), Theoharides
patent: 6020305 (2000-02-01), Theoharides
patent: 6132724 (2000-10-01), Blum
patent: 6136795 (2000-10-01), Florio
patent: 6162787 (2000-12-01), Sorgente et al.
patent: 6211195 (2001-04-01), Webb et al.
patent: 6586448 (2003-07-01), DeNinno et al.
patent: 6689748 (2004-02-01), Theoharides
patent: 6765008 (2004-07-01), Chen
patent: 7482029 (2009-01-01), Cohen
patent: 2001/0000340 (2001-04-01), Chen et al.
patent: 2002/0146393 (2002-10-01), Bell et al.
patent: 2005/0220909 (2005-10-01), Theoharides
patent: 2006/0210551 (2006-09-01), Lindsberg et al.
patent: 2007/0141187 (2007-06-01), Theoharides
patent: 0426479 (1991-05-01), None
patent: 2105193 (1984-09-01), None
patent: WO-9833494 (1998-08-01), None
patent: WO-0078320 (2000-12-01), None
Papaloidis et al. The Flavonoid Luteolin Inhibits Niacin-Induced Flush; British Journal of Pharmacology (2008) 153, pp. 1382-1387.
Phillipson, J. New Drugs From Nature—It Could Be Yew; Phytotherapy Research 13 (1999) pp. 2-8.
Revilla et al. Comparison of Several Procedures Used for the Extraction of Anthocynains From Red Grapes; J. Agric. Food Chem. 1998, 46, pp. 4592-4597.
International Search Report and Written Opinion, International Patent Application No. PCT/US08/86059, mailed Jan. 26, 2009 (2 pages).
Russell, A.L. and McCarty, M.F. “Glucosamine for migraine prophylaxis?” Medical Hypotheses, 55(3): 195-198 (2000).
Matsuda, K. et al., “Inhibitory Effects of Sialic-Acid- or N-Acetylglucosamine-Specific Lectins on Histamine Release Induced by Compound 48/80, Bradykinin and a Polyethylenimine in Rat Peritoneal Mast Cells,” Jpn. J. Pharmacol., 64: 1-8 (1994).
Trichopoulou, A. et al., “Cancer and Meditarranean Dietary Traditions,” Cancer Epidemiology, Biomarkers, & Prevention, vol. 9: 869-873 (Sep. 2000).
Theoharides, T.C., “The Mast Cell: A Neuroimmunoendocrine Master Player,” Int. J. Tiss. Reac. XVIII(1), 1-21 (1996).
Theoharides, T.C., “Histamine2 (H2)-Receptor Antagonists in the Treatment of Urticaria,” Drugs 37: 345-355 (1989).
Theoharides, T. “Mast Cells and Migraines,” Brief Proposal, (1983).
Morrow, J. et al., “Indentification of Skin as a Major Site of Prostaglandin D2 Release Following Oral Administration of Niacin in Human,” J. Invest. Derm., vol. 98(5): 812-815 (1992).
Weston, A. et al., “Terminal Ileal Mucosal Mast Cells in Irritable Bowel Syndrome,” Dig. Diseases and Sci., vol. 38(9): 1590-1595 (Sep. 1993).
Shapiro, G. et al., “Cromolyn Sodium: A Review,” Pharmacotherapy, vol. 5(3): 156-170 (May/Jun. 1985).
Database WPI: 2001-358435—XP002221703, “Compositions comprising hyaluronic acid and flavonoids,” (2 pages).
International Search Report issued for PCT/US02/00476, dated Dec. 16, 2002 (6 pages).
Parodi et al., Arch. Psicol. Neurol. Psichiatr. vol. 49(3): 299-303 (1988).
Split et al., “Ketotifen in the Treatment of Chronic Cluster Headache,” Headache, vol. 24(30: 147-148: 1984).
Unlisted Drugs, vol. 20(11): 167 (Nov. 1968).
Debeuckelaere, et al., “Systemic Mast Cell Disease: A review of the literature with special focus on the gastrointestinal manifestations”, Acta clinica Belgica, 46, 226-232 (1991).
Koblenzer, C.S. “Neurotic excoriations and dermatitis artefacta,” Dermatologic Clinics, vol. 14(3): 447-455 (Jul. 1996).
Tauberg, J. et al., “Stress-induced urticaria associated with local anesthetic administration,” Anesthesia Progress, vol. 30(6): 199-200 (1983).
Theoharides, T.C. “Mast Cells: The Immune Gate To The Brain,” Life Sciences, vol. 46: 607-617 (1990).
Lambracht-Hall, M. et al., “Serotonin Release From Rat Brain Mast Cells in Vitro,” Neuroscience, vol. 39(1) 199-207 (1990).
Dimitriadou, V. et al., Histochemical and Ultrastructural Characteristics of Rat Brain Perivascular Mast Cells Stimulated With Compound 48/80 and Carbachol, Neuroscience, vol. 39(1): 209-224 (1990).
Pearce, F.L. “Mast cell heterogeneity,” TIPS: 165-167 (Apr. 1983).
Theoharides, T.C. and Douglas, W.W. “Somatostatin Induces Histamine Secretion From Rat Peritoneal Mast Cells,” Endocrinology, vol. 102(5): 1637-1640) (Nov. 7, 1977).
Sundaram, K. et al., “Antagonists of luteinizing hormone releasing hormone bind to rat mast cells and induce histamine release,” Agents and Actions, vol. 25(3/4): 307-313 (1988).
Mathias, J. et al., “Debilitating ‘Functional’ Bowel Disease Controlled by Leuprolide Acetate, Gonadotropin-Releasing Hormone (GnRH) Analog,” Digestive Diseases and Sciences, vol. 34(5): 761-766 (May 1989).
Read, N.W. “Irritable bowel syndrome (IBS)—definition and pathophysiology,”, vol. 130: 7-13 (1987).
Stefanini, G.F. et al., “Oral disodium cromoglycate treatment on irritable bowel syndrome: An open study on 101 subjects with diarrheic type,” vol. 87: 55-57 (1992).
International Search Report issued for PCT/US95/01392, dated May 31, 1995 (4 pages).
Hendriks, J. et al., “Flavonoids Influence Monocytic CTPase Activity and Are Protective in Experimental Allergic Encephalitis,” J. Exp. Med., vol. 200(12): 1667-1672 (2004).
Mezzapesa, D. et al., “Glatiramer acetate in multiple sclerosis,” Expert Rev. Neurotherapeutics (5)4: 451-458 (2005).
Gupta, E. et al., “Lovastatin and Extended-Release Niacin Combination Product: The First Drug Combination for the Management of Hyperlipidia,” Heart Disease, vol. 4, 124-137 (2002).
Owens, M.J. and Nemeroff, C.B., “Physiology and Pharmacology of Corticotropin-releasing Factor,” Pharmacological Reviews, vol. 43(4): 425-615 (1991).
Devlin, Thomas (ed): Textbook of Biochemistry with Clinical Correlations, 2nd Edition: Ch. 8.5-8.6, 345-351 (1982).
Simopoulos, A.P., Visioli F. (eds): Mediterranean Diets. World Rev. Nutr. Diet. Basel, Karger, vol. 87: 56-77 (2000).
Urade, Y. et al., “The Major Source of Endogenous Prostaglandin D2 Production is Likely Antigen-Presenting Cells,” J. Immunol., 143(9): 2982-2989 (Nov. 1, 1989).
Lidor, C. et al., “Osteoporosis as the Sole Presentation of Bone Marrow Mastocytosis,” J. Bone Min Res., vol. 5(8): 871-876 (1990).
Kimata, M. et al., “Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells,” Clin. and Exper. Allergy, vol. 30, 501-508 (2000).
Letters to the Editor, J. Allergy Clin. Immunol., vol. 119(2): 498-499 (Oct. 18, 2006).
Irani, A-M, et al., “Mast Cell Changes in Scleroderma,” Arth. and Rheuma., vol. 35(8): 933-939 (Aug. 1992).
Dunn, R.T. et al., “Low-Dose Aspirin and Ibuprofen Reduce The Cutaneous Reactions Following Niacin Administration,” Am. J. Thera., 2: 478-480 (1995).
Dvorak, A.M. et al., “Human Gut Mucosal Mast Cell: Ultrastructural Observations and Anatomic Varia
Leith Patricia
Theta Biomedical Consulting & Development Co., Inc.
Wilmer Cutler Pickering Hale & Dorr LLP.
LandOfFree
Method for protecting humans against superficial vasodilator... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for protecting humans against superficial vasodilator..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for protecting humans against superficial vasodilator... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2628972